Clinical Trial: A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Melanoma
Study Type: INTERVENTIONAL
Official Title: A Phase II Study of IO102/IO103 and Nivolumab-relatlimab Fixed Dose Combination in Untreated, Unresectable Stage III/IV Melanoma
Brief Summary:
The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma.
Read more